Praxis Precision Medicines, Inc. (Nasdaq: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into ...

Cryptocurrency listings have outperformed the average of traditional stock listings, despite recent community criticism ...

Immunome, Inc. (the "Company") (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced today that on April 1, 2025, the ...

The listing, which includes both its primary shares on Nasdaq and its warrants on the Texas exchange, marks a significant milestone amid intensifying competition among stock exchanges. This ...

We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look ...

Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, today announced that, in ...

We recently published a list of 11 Best Performing NASDAQ Stocks So Far in 2025. In this article, we are going to take a look ...

Market Valuation and Liquidity: At $2.2 billion, Kyivstar is trading at 3.6x EV/EBITDA, well below its global peers’ average.

Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, granted stock options to purchase 43,650 ...

TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today ...

Iovance Biotherapeutics, Inc. aims to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a ...